GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
MWN-AI** Summary
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical-stage immuno-oncology company specializing in innovative therapeutics informed by its proprietary TriKE® (T-cell Engager) platform, is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. Michael Breen, the Executive Chairman and Chief Executive Officer, will represent the company at this prominent industry event, where investors can coordinate one-on-one meetings through their H.C. Wainwright contacts.
Currently, GT Biopharma is in the midst of a Phase 1 trial evaluating its investigational drug GTBP-3650 for the treatment of relapsed or refractory CD33-expressing hematologic malignancies. The trial continues to enroll participants as planned, and initial data from several dose cohorts is anticipated to be released later in 2025. This research underlines the company's commitment to unveiling innovative treatment options for challenging cancers.
Moreover, the company is preparing for the submission of an Investigational New Drug (IND) application for its GTB-5550 TriKE® product, aimed at targeting B7H3 positive solid tumors, with a submission timeline set for the fourth quarter of 2025. This highlights GT Biopharma’s aggressive advancement in multi-faceted therapeutic development within the immuno-oncology landscape.
In addition to the conference, an on-demand webcast of the company's presentation will be available starting at 7:00 a.m. ET on September 5, 2025. Investors and interested parties can access this via the company's IR Calendar webpage. As GT Biopharma continues to navigate the clinical trial landscape, the advancements and updates on its pipeline are closely watched indicators of its future trajectory.
For more details on GT Biopharma, the company’s website provides comprehensive information about its research and strategic goals.
MWN-AI** Analysis
GT Biopharma (NASDAQ: GTBP) is set to showcase its innovative pipeline at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. A key focus will be its Phase 1 trial of GTBP-3650, targeting relapsed or refractory CD33 expressing hematologic malignancies. The company’s strategic emphasis on this indication suggests potential upsides for stakeholders as initial dose cohort results are expected in late 2025.
Investors should pay close attention to the company’s developmental timelines. The upcoming IND submission for GTB-5550 TriKE® for B7H3 positive solid tumors in Q4 2025 signifies a promising expansion of their pipeline. This product, leveraging the TriKE® platform, aims to capitalize on the efficacy of natural killer (NK) cells, representing a significant advancement in immunotherapy. Hence, announcements around these key milestones could greatly influence market sentiment and stock performance.
The one-on-one meetings available at the conference offer investors a unique opportunity to glean insights directly from the management team, particularly from CEO Michael Breen. Engaging with management could provide an understanding of their strategic vision and operational execution, which has implications for future growth.
Analysts should monitor market reactions post-conference, especially if the company releases any new data or guidance. Positive trial updates or regulatory progress could spur renewed investor interest and potentially uplift share prices. Conversely, any delays or adverse results may lead to declines, underscoring the inherent volatility associated with clinical-stage biopharmaceutical investments.
Overall, while GT Biopharma's pipeline presents promise, it is essential for investors to weigh potential risks against the backdrop of ongoing trials and market reactions, particularly as the company continues its trajectory towards addressing significant unmet medical needs in cancer treatment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City
Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to enroll as expected, and the Company remains on track to release initial results from multiple dose cohorts later in 2025
Company remains on track for GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors in Q4 2025
SAN FRANCISCO, CALIFORNIA, Sept. 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE ® platform, today announced that Michael Breen, Executive Chairman and Chief Executive Office of GT Biopharma, will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City. Investors interested in scheduling a one-on-one meeting can contact their H.C. Wainwright representative.
H.C. Wainwright 27th Annual Global Investment Conference – September 8-10, 2025
An on-demand webcast of the Company's presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, through the webcast link below as well as on the Company’s IR Calendar webpage.
Webcast link: https://journey.ct.events/view/49bd1b10-7737-4350-8079-4b8fb31e8c3d
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE ® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE ® technology. For more information, please visit gtbiopharma.com .
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE ® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ**
What specific milestones does GT Biopharma Inc. (GTBP) anticipate achieving from the Phase 1 trial of GTBP-3650 for r/r CD33 expressing hematologic malignancies before the initial results release in late 2025?
How does GT Biopharma Inc. (GTBP) plan to position GTB-5550 TriKE® in the competitive landscape of therapies for B7H3 positive solid tumors upon its expected IND submission in Q4 2025?
What learnings from previous trials, if any, is GT Biopharma Inc. (GTBP) applying to enhance the design and execution of the ongoing Phase 1 trial for GTBP-3650?
Can you elaborate on the strategic partnership with the University of Minnesota and how it enhances GT Biopharma Inc. (GTBP)'s capabilities in developing the TriKE® platform?
**MWN-AI FAQ is based on asking OpenAI questions about GT Biopharma Inc. (NASDAQ: GTBP).
NASDAQ: GTBP
GTBP Trading
-6.32% G/L:
$0.4122 Last:
1,787,553 Volume:
$0.4508 Open:
